click below
click below
Normal Size Small Size show me how
Antihyperlipid 411
Antihyperlipidemic Drugs
| Question | Answer |
|---|---|
| LDL goal w/o CHD < 2 RF | < 160 mg/dl |
| LDL goal w/o CHD 2+ RF | < 130 mg/dl |
| LDL goal w/ CHD or risk equivalents (DM or multiple risk factors) | < 70-100 mg/dl |
| Bind bile acids in intestine, prevent fat abs | Bile Acid Sequestrants MOA |
| Belching, bloating, constipation, unpleasant taste | Bile Acid Sequestrants ADRs |
| Cholestyramine, Colestipol, Colesevelam | Bile Acid Sequestrants |
| Reduction in hepatic production of VLDL (Lowers LDL) | Niacin |
| Flushing, pruritus, rash, uticaria | Niacin |
| #1 Hepatotoxicity, gastritis/GI bleeding, hyperglycemia, gout, myalgias | Niacin ADRs |
| Diabetes, active gout, PUD, severe gastritis | Niacin contraindications |
| Inhibition of intracellular synthesis of cholesterol | HMG CoA Reductase Inhibitors (Statins) MOA |
| Hepatotoxicity, myopathy | HMG CoA Reductase Inhibitors (Statins) MOA |
| Lower LDL | Statins |
| Best drug to raise HDL | Niacin |
| Catabolism of VLDL | FIbric Acid Derivitaves |
| Dyspepsia, abdominal pain | Common ADRs of Fibric Acid Derivatives |
| Gemfibrozil | FIbric Acid Derivative |
| Fenofibrate | FIbric Acid Derivative |
| Ezetimibe | FIbric Acid Derivative |
| Cholilithiasis, myopathy, hepatitis | Potentially serious ADRs of Fibric Acid Derivatives |
| Inhibits transport of cholesterol across intestinal wall | Ezetimibe MOA |
| Monotherapy or combo therapy w/ statins for treatment of primary hypercholesterolemia (approx 15% reduction in LDL) | Ezetimibe |
| Active liver disease, persistently elevated serum transaminases | Ezetimibe Contraindications |